UK Markets closed

Lonza Group AG (0QNO.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
547.80+14.68 (+2.75%)
At close: 06:16PM BST

Lonza Group AG

Muenchensteinerstrasse 38
Basel 4002
Switzerland
41 61 316 81 11
https://www.lonza.com

Sector(s)Healthcare
IndustryMedical Laboratories & Research
Full-time employees16,218

Key executives

NameTitlePayExercisedYear born
Dr. Pierre-Alain Ruffieux Ph.D.Chief Exec. Officer2.64MN/A1969
Mr. Philippe DeeckeChief Financial OfficerN/AN/A1972
Mr. Stefan StoffelHead of Group OperationsN/AN/A1966
Mr. Dirk OehlersVP of Investor RelationsN/AN/AN/A
Mr. Andreas BohrerGroup Gen. Counsel & Company Sec.N/AN/AN/A
Ms. Victoria MorganHead of External CommunicationsN/AN/AN/A
Ms. Jennifer ClancySr. Director of Global MarketingN/AN/AN/A
Ms. Caroline BarthChief HR OfficerN/AN/A1972
Ms. Constance WardHead of External CommunicationsN/AN/AN/A
Dr. Sanna FowlerHead of External CommunicationsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.

Description

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.

Corporate governance

Lonza Group AG’s ISS governance QualityScore as of 1 May 2022 is 1. The pillar scores are Audit: 5; Board: 1; Shareholder rights: 1; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.